{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:10:53Z","timestamp":1790089853979,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1185180"],"award-info":[{"award-number":["1185180"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00415-024-12732-3","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T12:22:05Z","timestamp":1734006125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-7645","authenticated-orcid":false,"given":"Dhamidhu","family":"Eratne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-3762","authenticated-orcid":false,"given":"Matthew J. Y.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4953-4500","authenticated-orcid":false,"given":"Samantha","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Walterfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Malpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Pedrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratishtha","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel F.","family":"Berkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9717-0820","authenticated-orcid":false,"given":"Alexander F.","family":"Santillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Velakoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The MiND Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Dobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaf","family":"Yassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Pantelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Stehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Farrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cath","family":"Kaylor-Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashida","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Goranitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Simpson-Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"12732_CR1","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/imj.15973","volume":"52","author":"PM Loveland","year":"2022","unstructured":"Loveland PM, Watson R, Yassi N (2022) Diagnostic challenges for dementia in Australia: are blood-based biomarkers the solution? Intern Med J 52:2181\u20132185. https:\/\/doi.org\/10.1111\/imj.15973","journal-title":"Intern Med J"},{"key":"12732_CR2","doi-asserted-by":"publisher","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH et al (2021) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol S1474442221003616. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6","DOI":"10.1016\/S1474-4422(21)00361-6"},{"key":"12732_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.5319","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G et al (2024) Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319","journal-title":"JAMA Neurol"},{"key":"12732_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","volume":"14","author":"S Baiardi","year":"2022","unstructured":"Baiardi S, Quadalti C, Mammana A et al (2022) Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther 14:153. https:\/\/doi.org\/10.1186\/s13195-022-01093-6","journal-title":"Alzheimers Res Ther"},{"key":"12732_CR5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S et al (2023) A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging 3:1079\u20131090. https:\/\/doi.org\/10.1038\/s43587-023-00471-5","journal-title":"Nat Aging"},{"key":"12732_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Pedrini S, Doecke JD et al (2023) Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimer\u2019s Dement 19:1117\u20131134. https:\/\/doi.org\/10.1002\/alz.12724","journal-title":"Alzheimer\u2019s Dement"},{"key":"12732_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/alz.13525","volume":"20","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Ferreira PCL, Gonz\u00e1lez-Escalante A et al (2023) A novel ultrasensitive assay for plasma p-tau217: performance in individuals with subjective cognitive decline and early Alzheimer\u2019s disease. Alzheimers Dement 20:1239\u20131249. https:\/\/doi.org\/10.1002\/alz.13525","journal-title":"Alzheimers Dement"},{"key":"12732_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J (2023) Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging 3:506\u2013519. https:\/\/doi.org\/10.1038\/s43587-023-00403-3","journal-title":"Nat Aging"},{"key":"12732_CR9","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD et al (2022) Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med 28:1398\u20131405. https:\/\/doi.org\/10.1038\/s41591-022-01822-2","journal-title":"Nat Med"},{"key":"12732_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13855","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist S, Tideman P, Mattsson-Carlgren N et al (2024) Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. https:\/\/doi.org\/10.1001\/jama.2024.13855","journal-title":"JAMA"},{"key":"12732_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S et al (2022) Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol 18:158\u2013172. https:\/\/doi.org\/10.1038\/s41582-021-00616-3","journal-title":"Nat Rev Neurol"},{"key":"12732_CR12","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A et al (2021) A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12:3400. https:\/\/doi.org\/10.1038\/s41467-021-23620-z","journal-title":"Nat Commun"},{"key":"12732_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1017\/neu.2023.25","volume":"36","author":"MJY Kang","year":"2024","unstructured":"Kang MJY, Eratne D, Dobson H et al (2024) Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders. Acta Neuropsychiatr 36:17\u201328. https:\/\/doi.org\/10.1017\/neu.2023.25","journal-title":"Acta Neuropsychiatr"},{"key":"12732_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0004867419857811","volume":"54","author":"D Eratne","year":"2020","unstructured":"Eratne D, Loi SM, Walia N et al (2020) A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: a \u201cC-reactive protein\u201d for psychiatrists and neurologists? Aust N Z J Psychiatry 54:57\u201367. https:\/\/doi.org\/10.1177\/0004867419857811","journal-title":"Aust N Z J Psychiatry"},{"key":"12732_CR15","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/alz.12549","volume":"18","author":"D Eratne","year":"2022","unstructured":"Eratne D, Loi SM, Li Q-X et al (2022) Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer\u2019s disease and frontotemporal disorders in clinical settings. Alzheimers Dement 18:2218\u20132233. https:\/\/doi.org\/10.1002\/alz.12549","journal-title":"Alzheimers Dement"},{"key":"12732_CR16","doi-asserted-by":"publisher","first-page":"120439","DOI":"10.1016\/j.jns.2022.120439","volume":"442","author":"D Eratne","year":"2022","unstructured":"Eratne D, Keem M, Lewis C et al (2022) Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors. J Neurol Sci 442:120439. https:\/\/doi.org\/10.1016\/j.jns.2022.120439","journal-title":"J Neurol Sci"},{"key":"12732_CR17","doi-asserted-by":"publisher","unstructured":"Eratne D, Kang MJY, Lewis C et al (2024) Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders. J Neurolog Sci 123291. https:\/\/doi.org\/10.1016\/j.jns.2024.123291","DOI":"10.1016\/j.jns.2024.123291"},{"key":"12732_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14278","author":"D Eratne","year":"2024","unstructured":"Eratne D, Kang MJY, Lewis C et al (2024) Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.14278","journal-title":"Alzheimers Dement"},{"key":"12732_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/00048674231187312","volume":"58","author":"D Eratne","year":"2024","unstructured":"Eratne D, Kang M, Malpas C et al (2024) Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders. Aust N Z J Psychiatry 58:70\u201381. https:\/\/doi.org\/10.1177\/00048674231187312","journal-title":"Aust N Z J Psychiatry"},{"key":"12732_CR20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/gps.4430","volume":"31","author":"B Draper","year":"2016","unstructured":"Draper B, Cations M, White F et al (2016) Time to diagnosis in young-onset dementia and its determinants: the INSPIRED study. Int J Geriatr Psychiatry 31:1217\u20131224. https:\/\/doi.org\/10.1002\/gps.4430","journal-title":"Int J Geriatr Psychiatry"},{"key":"12732_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/imj.13099","volume":"46","author":"B Draper","year":"2016","unstructured":"Draper B, Withall A (2016) Young onset dementia. Intern Med J 46:779\u2013786. https:\/\/doi.org\/10.1111\/imj.13099","journal-title":"Intern Med J"},{"key":"12732_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1017\/S1041610220001489","volume":"34","author":"SM Loi","year":"2022","unstructured":"Loi SM, Goh AMY, Mocellin R et al (2022) Time to diagnosis in younger-onset dementia and the impact of a specialist diagnostic service. Int Psychogeriatr 34:367\u2013375. https:\/\/doi.org\/10.1017\/S1041610220001489","journal-title":"Int Psychogeriatr"},{"key":"12732_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/gps.5424","volume":"36","author":"SM Loi","year":"2021","unstructured":"Loi SM, Eratne D, Goh AMY et al (2021) A 10 year retrospective cohort study of inpatients with younger-onset dementia. Int J Geriatr Psychiatry 36:294\u2013301. https:\/\/doi.org\/10.1002\/gps.5424","journal-title":"Int J Geriatr Psychiatry"},{"key":"12732_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1176\/appi.neuropsych.20100266","volume":"34","author":"P Tsoukra","year":"2022","unstructured":"Tsoukra P, Velakoulis D, Wibawa P et al (2022) The diagnostic challenge of young-onset dementia syndromes and primary psychiatric diseases: results from a retrospective 20-year cross-sectional study. J Neuropsychiatry Clin Neurosci 34:44\u201352. https:\/\/doi.org\/10.1176\/appi.neuropsych.20100266","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"12732_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB et al (2021) Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol 20:484\u2013496. https:\/\/doi.org\/10.1016\/S1474-4422(21)00066-1","journal-title":"Lancet Neurol"},{"key":"12732_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-020-00595-5","volume":"12","author":"JD Doecke","year":"2020","unstructured":"Doecke JD, Ward L, Burnham SC et al (2020) Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther 12:36. https:\/\/doi.org\/10.1186\/s13195-020-00595-5","journal-title":"Alzheimers Res Ther"},{"key":"12732_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3233\/JAD-150247","volume":"48","author":"Q-X Li","year":"2015","unstructured":"Li Q-X, Villemagne VL, Doecke JD et al (2015) Alzheimer\u2019s disease normative cerebrospinal fluid biomarkers validated in PET amyloid-\u03b2 characterized subjects from the Australian imaging, biomarkers and lifestyle (AIBL) study. J Alzheimers Dis 48:175\u2013187. https:\/\/doi.org\/10.3233\/JAD-150247","journal-title":"J Alzheimers Dis"},{"key":"12732_CR28","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Zetterberg H, Mattsson N et al (2015) Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85. https:\/\/doi.org\/10.1212\/WNL.0000000000001991","DOI":"10.1212\/WNL.0000000000001991"},{"key":"12732_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010. J Neuropathol Exp Neurol 71:266\u2013273. https:\/\/doi.org\/10.1097\/NEN.0b013e31824b211b","journal-title":"J Neuropathol Exp Neurol"},{"key":"12732_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40120-017-0069-5","volume":"6","author":"MN Sabbagh","year":"2017","unstructured":"Sabbagh MN, Lue L-F, Fayard D, Shi J (2017) Increasing precision of clinical diagnosis of Alzheimer\u2019s disease using a combined algorithm incorporating clinical and novel biomarker data. Neurol Ther 6:83\u201395. https:\/\/doi.org\/10.1007\/s40120-017-0069-5","journal-title":"Neurol Ther"},{"key":"12732_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimer\u2019s Dement"},{"key":"12732_CR32","doi-asserted-by":"publisher","first-page":"e12548","DOI":"10.1002\/dad2.12548","volume":"16","author":"Z Wang","year":"2024","unstructured":"Wang Z, Lewis V, Stehmann C et al (2024) Alzheimer\u2019s disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt-Jakob disease. Alz Dem Diag Ass Dis Mo 16:e12548. https:\/\/doi.org\/10.1002\/dad2.12548","journal-title":"Alz Dem Diag Ass Dis Mo"},{"key":"12732_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"H Hampel","year":"2021","unstructured":"Hampel H, Cummings J, Blennow K et al (2021) Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 17:580\u2013589. https:\/\/doi.org\/10.1038\/s41582-021-00520-w","journal-title":"Nat Rev Neurol"},{"key":"12732_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/00048674221084245","volume":"56","author":"D Eratne","year":"2022","unstructured":"Eratne D, Li Q-X, Loi SM et al (2022) Cerebrospinal fluid Alzheimer disease biomarkers for assessing cognitive and neuropsychiatric symptoms: expanding the \u201ctoolkit\u201d in the psychiatrist\u2019s diagnostic armamentarium. Aust N Z J Psychiatry 56:865\u2013866. https:\/\/doi.org\/10.1177\/00048674221084245","journal-title":"Aust N Z J Psychiatry"},{"key":"12732_CR35","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/brainsci11101352","volume":"11","author":"G Pandolfo","year":"2021","unstructured":"Pandolfo G, Iannuzzo F, Genovese G et al (2021) Mental illness and amyloid: a scoping review of scientific evidence over the last 10 years (2011 to 2021). Brain Sci 11:1352. https:\/\/doi.org\/10.3390\/brainsci11101352","journal-title":"Brain Sci"},{"key":"12732_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","volume":"78","author":"NSM Schoonenboom","year":"2012","unstructured":"Schoonenboom NSM, Reesink FE, Verwey NA et al (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78:47\u201354. https:\/\/doi.org\/10.1212\/WNL.0b013e31823ed0f0","journal-title":"Neurology"},{"key":"12732_CR37","doi-asserted-by":"publisher","unstructured":"Dubois B, Feldman HH, Jacova C et al (2014) Position paper advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. WwwThelancetCom\/Neurology 13. https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0","DOI":"10.1016\/S1474-4422(14)70090-0"},{"key":"12732_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002923","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K et al (2016) A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000002923","journal-title":"Neurology"},{"key":"12732_CR39","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H et al (2021) Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol 78:1375. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3180","journal-title":"JAMA Neurol"},{"key":"12732_CR40","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/brain\/awac158","volume":"146","author":"EM Vromen","year":"2023","unstructured":"Vromen EM, de Boer SCM, Teunissen CE et al (2023) Biomarker A+T\u2212: is this Alzheimer\u2019s disease or not? A combined CSF and pathology study. Brain 146:1166\u20131174. https:\/\/doi.org\/10.1093\/brain\/awac158","journal-title":"Brain"},{"key":"12732_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A et al (2021) Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20:739\u2013752. https:\/\/doi.org\/10.1016\/S1474-4422(21)00214-3","journal-title":"Lancet Neurol"},{"key":"12732_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02570-4","volume":"146","author":"L Yu","year":"2023","unstructured":"Yu L, Boyle PA, Janelidze S et al (2023) Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathol 146:1\u201311. https:\/\/doi.org\/10.1007\/s00401-023-02570-4","journal-title":"Acta Neuropathol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12732-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:42:16Z","timestamp":1738172536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12732-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["12732"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12732-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"21 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). SL has received honorarium from Lundbeck and Otsuka. AHE has received honoraria from Abbvie, STADA, Seqirus, and Ipsen. KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. All the other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of interests and financial disclosures"}},{"value":"Dr Dhamidhu Eratne.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistical analysis conducted by"}},{"value":"All human subjects provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent statement"}}],"article-number":"25"}}